← ImmunityBio, Inc. (IBRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
ImmunityBio, Inc. (IBRX)
Biological Products, (No Diagnostic Substances) · market cap $9.3B · as of 2026-09-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
ImmunityBio (IBRX) trades at ~$9.29 on ~1.047B shares for a ~$9.73B market cap, with reported revenue inflecting from $1M (2023) to $15M (2024) to $113M (2025) against a $351M net loss and $208M of R&D in 2025 — a profile consistent with a company in the early innings of a commercial launch while still burning heavily. Our structured coverage of this name is limited: no pipeline programs, no lead asset, and no dated catalysts are in our database, so the clinical and regulatory architecture behind that revenue ramp is not in our coverage rather than absent. The single most quantifiable tension in what we do have is balance-sheet: $205.2M cash against a burn that our model scores at roughly 8.2 months of runway, set against a valuation of ~86x trailing revenue.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
-1.7%
6-month
+30.0%
12-month
+277.2%
52-wk range
$1.98–$11.55
vs 50-day MA
+16.9%
vs 200-day MA
+29.5%
Realized vol
99.5%
Max drawdown
-69.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IBRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.